Table of Contents
ISRN Chromatography
Volume 2012, Article ID 761679, 10 pages
http://dx.doi.org/10.5402/2012/761679
Research Article

Application of a Reliable LC-MS/MS Method for Determination of Rizatriptan in Healthy Subject Samples: Demonstration of Assay Reproducibility by Incurred Sample Reanalysis

1Department of Chemistry, Pramukh Swami Science & H. D. Patel Arts College, Sarva Vidyalaya Campus, Kadi 382 715, Gujarat, India
2Bioanalytical Laboratory, Cliantha Research Ltd., Bodakdev, Ahmedabad 380054, Gujarat, India
3Department of Chemistry, School of Sciences, Gujarat University, Navrangpura, Ahmedabad 380009, Gujarat, India
4Department of Chemistry, St. Xavier’s College, Navrangpura, Ahmedabad 380009, Gujarat, India

Received 7 October 2012; Accepted 29 October 2012

Academic Editors: C. Y. Choo and A. Namera

Copyright © 2012 Dinesh S. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Deleu and Y. Hanssens, “Current and emerging second-generation triptans in acute migraine therapy: a comparative review,” Journal of Clinical Pharmacology, vol. 40, no. 7, pp. 687–700, 2000. View at Google Scholar · View at Scopus
  2. M. J. A. Láinez, “Rizatriptan in the treatment of migraine,” Neuropsychiatric Disease and Treatment, vol. 2, no. 3, pp. 247–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. G. H. Dahlof, A. M. Rapoport, F. D. Sheftell, and C. R. Lines, “Rizatriptan in the treatment of migraine,” Clinical Therapeutics, vol. 21, no. 11, pp. 1823–1836, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Goadsby, “Serotonin 5-HT1B/1D receptor agonists in migraine: Comparative pharmacology and its therapeutic implications,” CNS Drugs, vol. 10, no. 4, pp. 271–286, 1998. View at Google Scholar · View at Scopus
  5. C. R. Shadle, G. Liu, and M. R. Goldberg, “A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers,” Journal of Clinical Pharmacology, vol. 40, no. 3, pp. 309–315, 2000. View at Google Scholar · View at Scopus
  6. S. K. Swan, H. Alcorn, A. Rodgers et al., “Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study,” Journal of Clinical Pharmacology, vol. 46, no. 2, pp. 172–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. R. Goldberg, Y. Lee, K. P. Vyas et al., “Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects,” Journal of Clinical Pharmacology, vol. 40, no. 1, pp. 74–83, 2000. View at Google Scholar · View at Scopus
  8. S. J. Tepper and R. C. Spears, “Acute treatment of migraine,” Neurologic Clinics, vol. 27, no. 2, pp. 417–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Barrish, T. V. Olah, G. J. Gatto, K. B. Michel, M. R. Dobrinska, and J. D. Gilbert, “The use of stable isotope labeling and liquid chromatography/tandem mass spectrometry techniques to study the pharmacokinetics and bioavailability of the antimigraine drug, MK-0462 (rizatriptan) in dogs,” Rapid Communications in Mass Spectrometry, vol. 10, pp. 1033–1037, 1996. View at Google Scholar
  10. K. P. Vyas, R. A. Halpin, L. A. Geer et al., “Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans,” Drug Metabolism and Disposition, vol. 28, no. 1, pp. 89–95, 2000. View at Google Scholar · View at Scopus
  11. J. Chen, X. Jiang, W. Jiang, N. Mei, X. Gao, and Q. Zhang, “Liquid chromatographic method for the determination of rizatriptan in human plasma,” Journal of Chromatography B, vol. 805, no. 1, pp. 169–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Chen, H. Miao, M. Lin et al., “Development and validation of a selective and robust LC-MS/MS method for high-throughput quantifying rizatriptan in small plasma samples: application to a clinical pharmacokinetic study,” Journal of Chromatography B, vol. 844, no. 2, pp. 268–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. F. Guo, A. J. Zhang, L. Zhao et al., “Determination of rizatriptan in human plasma by liquid chromatographic-eletrospray tandem mass spectrometry: application to a pharmacokinetic study,” Biomedical Chromatography, vol. 20, no. 1, pp. 61–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Mogili, K. Kanala, B. R. Challa, B. R. Chandu, and C. K. Bannoth, “Determination of rizatriptan in human plasma by liquid chromatography stable isotope dilution electrospray MS-MS for application in bioequivalence study,” Chromatographia, vol. 74, pp. 585–592, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. McLoughlin, T. V. Olah, J. D. Ellis, J. D. Gilbert, and R. A. Halpin, “Quantitation of the 5HT1D agonists MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry,” Journal of Chromatography A, vol. 726, no. 1-2, pp. 115–124, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Vishwanathan, M. G. Bartlett, and J. T. Stewart, “Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 14, pp. 168–172, 2000. View at Google Scholar
  17. Guidance for Industry, Bionanlytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), 2001.
  18. B. K. Matuszewski, M. L. Constanzer, and C. M. Chavez-Eng, “Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS,” Analytical Chemistry, vol. 75, no. 13, pp. 3019–3030, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. R. King, R. Bonfiglio, C. Fernandez-Metzler, C. Miller-Stein, and T. Olah, “Mechanistic investigation of ionization suppression in electrospray ionization,” Journal of the American Society for Mass Spectrometry, vol. 11, no. 11, pp. 942–950, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), 1996.
  21. M. Yadav and P. S. Shrivastav, “Incurred sample reanalysis: a decisive tool in bioanalytical research,” Bioanalysis, vol. 3, pp. 1007–1024, 2011. View at Google Scholar
  22. H. Cheng, W. J. Polvino, D. Sciberras et al., “Pharmacokinetics and food interaction of MK-462 in healthy males,” Biopharmaceutics and Drug Disposition, vol. 17, pp. 17–24, 1996. View at Google Scholar